FDA Requires Conventional and Atypical Antipsychotics to Warn of Increased Death Risk in Elderly Dementia

The US Food and Drug Administration (FDA) announced that manufacturers of conventional antipsychotics are now required to add warnings to labels and prescribing information to indicate that these drugs are linked with an increased risk for death in elderly patients with dementia-related behavioral problems.